Logo image of ACB

AURORA CANNABIS INC (ACB) Stock Fundamental Analysis

USA - NASDAQ:ACB - CA05156X8504 - Common Stock

5.96 USD
-0.27 (-4.33%)
Last: 9/30/2025, 8:00:01 PM
5.9009 USD
-0.06 (-0.99%)
After Hours: 9/30/2025, 8:00:01 PM
Fundamental Rating

3

Taking everything into account, ACB scores 3 out of 10 in our fundamental rating. ACB was compared to 196 industry peers in the Pharmaceuticals industry. ACB may be in some trouble as it scores bad on both profitability and health. ACB is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year ACB has reported negative net income.
In the past year ACB had a positive cash flow from operations.
In the past 5 years ACB reported 4 times negative net income.
ACB had negative operating cash flow in 4 of the past 5 years.
ACB Yearly Net Income VS EBIT VS OCF VS FCFACB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1B -2B -3B

1.2 Ratios

ACB has a Return On Assets of -2.32%. This is in the better half of the industry: ACB outperforms 76.02% of its industry peers.
ACB has a Return On Equity of -3.53%. This is in the better half of the industry: ACB outperforms 77.55% of its industry peers.
Industry RankSector Rank
ROA -2.32%
ROE -3.53%
ROIC N/A
ROA(3y)-55.32%
ROA(5y)-62.11%
ROE(3y)-90.28%
ROE(5y)-91.51%
ROIC(3y)N/A
ROIC(5y)N/A
ACB Yearly ROA, ROE, ROICACB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150 -200 -250

1.3 Margins

ACB's Gross Margin of 4.04% is in line compared to the rest of the industry. ACB outperforms 49.49% of its industry peers.
ACB's Gross Margin has declined in the last couple of years.
ACB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 4.04%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-29.39%
ACB Yearly Profit, Operating, Gross MarginsACB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800 -1K

More info and screens

3

2. Health

2.1 Basic Checks

ACB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ACB has been increased compared to 1 year ago.
Compared to 5 years ago, ACB has less shares outstanding
ACB has a better debt/assets ratio than last year.
ACB Yearly Shares OutstandingACB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
ACB Yearly Total Debt VS Total AssetsACB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B 5B

2.2 Solvency

Based on the Altman-Z score of -9.18, we must say that ACB is in the distress zone and has some risk of bankruptcy.
ACB has a Altman-Z score of -9.18. This is in the lower half of the industry: ACB underperforms 67.86% of its industry peers.
ACB has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of ACB (0.07) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z -9.18
ROIC/WACCN/A
WACC9.23%
ACB Yearly LT Debt VS Equity VS FCFACB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B 4B

2.3 Liquidity

ACB has a Current Ratio of 2.97. This indicates that ACB is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.97, ACB is in line with its industry, outperforming 56.12% of the companies in the same industry.
ACB has a Quick Ratio of 1.51. This is a normal value and indicates that ACB is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of ACB (1.51) is worse than 60.20% of its industry peers.
Industry RankSector Rank
Current Ratio 2.97
Quick Ratio 1.51
ACB Yearly Current Assets VS Current LiabilitesACB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

ACB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.79%, which is quite impressive.
ACB shows a strong growth in Revenue. In the last year, the Revenue has grown by 28.42%.
Measured over the past years, ACB shows a small growth in Revenue. The Revenue has been growing by 6.94% on average per year.
EPS 1Y (TTM)44.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-307.69%
Revenue 1Y (TTM)28.42%
Revenue growth 3Y11.86%
Revenue growth 5Y6.94%
Sales Q2Q%17.48%

3.2 Future

Based on estimates for the next years, ACB will show a very strong growth in Earnings Per Share. The EPS will grow by 103.58% on average per year.
ACB is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.42% yearly.
EPS Next Y-288.53%
EPS Next 2Y206.48%
EPS Next 3Y81.3%
EPS Next 5Y103.58%
Revenue Next Year8.72%
Revenue Next 2Y7.21%
Revenue Next 3Y6.04%
Revenue Next 5Y7.42%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
ACB Yearly Revenue VS EstimatesACB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M 400M 500M
ACB Yearly EPS VS EstimatesACB Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -5 -10

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

ACB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
ACB is valuated rather expensively with a Price/Forward Earnings ratio of 17.68.
Based on the Price/Forward Earnings ratio, ACB is valued a bit cheaper than the industry average as 77.04% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of ACB to the average of the S&P500 Index (23.18), we can say ACB is valued slightly cheaper.
Industry RankSector Rank
PE N/A
Fwd PE 17.68
ACB Price Earnings VS Forward Price EarningsACB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACB Per share dataACB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

ACB's earnings are expected to grow with 81.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y206.48%
EPS Next 3Y81.3%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ACB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AURORA CANNABIS INC

NASDAQ:ACB (9/30/2025, 8:00:01 PM)

After market: 5.9009 -0.06 (-0.99%)

5.96

-0.27 (-4.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-06 2025-08-06/bmo
Earnings (Next)11-04 2025-11-04/bmo
Inst Owners15.09%
Inst Owner Change-26.77%
Ins Owners0.03%
Ins Owner ChangeN/A
Market Cap335.25M
Analysts73.33
Price Target5.86 (-1.68%)
Short Float %11.68%
Short Ratio4.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-321.48%
Min EPS beat(2)-426.74%
Max EPS beat(2)-216.23%
EPS beat(4)1
Avg EPS beat(4)935.07%
Min EPS beat(4)-426.74%
Max EPS beat(4)4494.06%
EPS beat(8)3
Avg EPS beat(8)450.07%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.04%
Min Revenue beat(2)-0.84%
Max Revenue beat(2)0.93%
Revenue beat(4)3
Avg Revenue beat(4)7.13%
Min Revenue beat(4)-0.84%
Max Revenue beat(4)14.66%
Revenue beat(8)6
Avg Revenue beat(8)3.86%
Revenue beat(12)7
Avg Revenue beat(12)2.68%
Revenue beat(16)9
Avg Revenue beat(16)2.74%
PT rev (1m)1.07%
PT rev (3m)-16.77%
EPS NQ rev (1m)55.57%
EPS NQ rev (3m)55.57%
EPS NY rev (1m)0%
EPS NY rev (3m)-127.78%
Revenue NQ rev (1m)0.26%
Revenue NQ rev (3m)10.44%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.5%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 17.68
P/S 1.31
P/FCF N/A
P/OCF 25.05
P/B 0.85
P/tB 1.01
EV/EBITDA N/A
EPS(TTM)-0.25
EYN/A
EPS(NY)0.34
Fwd EY5.66%
FCF(TTM)0
FCFYN/A
OCF(TTM)0.24
OCFY3.99%
SpS4.57
BVpS7.04
TBVpS5.88
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.32%
ROE -3.53%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 4.04%
FCFM N/A
ROA(3y)-55.32%
ROA(5y)-62.11%
ROE(3y)-90.28%
ROE(5y)-91.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-29.39%
F-Score6
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 81.56%
Cap/Sales 5.24%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.97
Quick Ratio 1.51
Altman-Z -9.18
F-Score6
WACC9.23%
ROIC/WACCN/A
Cap/Depr(3y)56.47%
Cap/Depr(5y)106.5%
Cap/Sales(3y)8.76%
Cap/Sales(5y)35.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-307.69%
EPS Next Y-288.53%
EPS Next 2Y206.48%
EPS Next 3Y81.3%
EPS Next 5Y103.58%
Revenue 1Y (TTM)28.42%
Revenue growth 3Y11.86%
Revenue growth 5Y6.94%
Sales Q2Q%17.48%
Revenue Next Year8.72%
Revenue Next 2Y7.21%
Revenue Next 3Y6.04%
Revenue Next 5Y7.42%
EBIT growth 1Y4.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year95.45%
EBIT Next 3Y29.76%
EBIT Next 5Y25.22%
FCF growth 1Y92.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y208.3%
OCF growth 3YN/A
OCF growth 5YN/A